Mounjaro, already on the market to treat Type 2 diabetes in the U.S., is going head to head with Novo’s drug. The stakes are enormous in need, expected to be over $30 billion by 2030, according to analysts at Cowen Inc. Novo Nordisk was projected to capture the largest share, with Wegovy sales topping $7 billion, but if Lilly’s head-to-head trials turn out well Mounjaro, and Lilly, could be huge winners.

Horizon’s CEO, Tim Walbert, will reportedly get around $135 million when the company is sold to Amgen. He has mastered a particular kind of industry expertise: taking drugs invented and tested by other people, wrapping them expertly in hard-nosed marketing and warm-hued patient relations, raising their prices, and enjoying astounding revenues without spending one dime on drug development.

Cancer death rates continued to decline among men, women, children, adolescents, and young adults in every significant racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. At a time when expensive new cancer treatments are increasing rapidly, patients have more therapy choices than ever before. Yet patients are kept mainly in the dark because their doctors either can’t or won’t communicate clearly.